MACOP-B regimen followed by involved-field radiation therapy in early-stage aggresive non-Hodgkin's lymphoma patients: 14-year update results

P. L. Zinzani, V. Stefoni, M. Tani, E. Barbieri, P. Albertini, E. Vigna, F. Gherlinzoni, L. Alinari, A. Galuppi, S. Pileri, L. Babini, S. Tura

Research output: Contribution to journalArticlepeer-review

Abstract

A single-center, retrospective study was conducted to evaluate therapeutic results of the MACOP-B third-generation chemotherapy regimen followed by involved-field radiation therapy in a stage I-II aggressive non-Hodgkin's lymphoma (NHL) patients. From 1986 to 1995, 118 consecutive patients with the diagnosis of aggressive NHL, stage I-IE or II-IIE, with or without bulky disease were treated with MACOP-B regimen followed, when appropriate, by 30-36 Gy involved-field radiation therapy The complete response (CR) rate was 95% after the combined modality treatment (97% for stage I-IE and 93% for stage II-IIE). Patients with bulky disease had a CR rate of 92%. Treatment was well tolerated and no deaths occurred from acute toxicity. After a median follow-up of 68 months, 24 (21%) patients relapsed. The 14-year projected relapse-free and overall survival rates were 78% and d 69%, respectively. MACOP-B regimen with/without involved-field radiation therapy provides a safe and effective combined modality treatment for early-stage aggressive NHL, with the possibility to definitively cure two thirds of the patients.

Original languageEnglish
Pages (from-to)989-995
Number of pages7
JournalLeukemia and Lymphoma
Volume42
Issue number5
Publication statusPublished - 2001

Keywords

  • Aggressive NHL
  • Early stage
  • Long-term follow-up
  • MACOP-B

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'MACOP-B regimen followed by involved-field radiation therapy in early-stage aggresive non-Hodgkin's lymphoma patients: 14-year update results'. Together they form a unique fingerprint.

Cite this